Tranexamic acid - Leading BioSciences

Drug Profile

Tranexamic acid - Leading BioSciences

Alternative Names: InflammaGen Shok-Pak; LB-1148

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator Leading BioSciences
  • Developer Leading BioSciences; VA San Diego Healthcare System
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator stimulants; Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiogenic shock; Multiple organ failure; Septic shock

Most Recent Events

  • 10 Aug 2016 Leading BioSciences receives patent allowance for tranexamic acid in USA
  • 22 Jul 2016 Leading Bioscience plans a phase II trial for Post-operative ileus and Post-surgery adhesions in USA (NCT02836470)
  • 06 Jun 2016 Leading BioSciences terminates a phase II trial in Septic shock in USA and Canada due to inability to enrol patients(NCT02317549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top